Fibrotic valvular heart disease subsequent to bromocriptine treatment

Cardiol Rev. 2002 Nov-Dec;10(6):334-6. doi: 10.1097/00045415-200211000-00005.

Abstract

Ergot alkaloids, such as ergotamine, have been associated with numerous vascular complications and with valvular heart disease. The authors describe a man who developed fibrosis of three heart valves during a 5-year treatment with bromocriptine for Parkinson disease. There were no other plausible causes. To our knowledge, such a side effect has never been described with this drug.

Publication types

  • Case Reports

MeSH terms

  • Bromocriptine / adverse effects*
  • Bromocriptine / therapeutic use
  • Fibrosis / chemically induced*
  • Fibrosis / diagnosis
  • Heart Valve Diseases / chemically induced*
  • Heart Valve Diseases / diagnosis
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy

Substances

  • Bromocriptine